# Nuvectis Pharma, Inc. (NVCT) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Nuvectis Pharma, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/NVCT/mda/fy2025/): filed 2026-02-11; accession 0001104659-26-013044 (https://www.sec.gov/Archives/edgar/data/1875558/000110465926013044/tmb-20251231x10k.htm); latest 10-K
- [FY 2024 MD&A](/company/NVCT/mda/fy2024/): filed 2025-02-25; accession 0001558370-25-001496 (https://www.sec.gov/Archives/edgar/data/1875558/000155837025001496/tmb-20241231x10k.htm)
- [FY 2023 MD&A](/company/NVCT/mda/fy2023/): filed 2024-03-05; accession 0001558370-24-002497 (https://www.sec.gov/Archives/edgar/data/1875558/000155837024002497/tmb-20231231x10k.htm)
- [FY 2022 MD&A](/company/NVCT/mda/fy2022/): filed 2023-03-08; accession 0001558370-23-003181 (https://www.sec.gov/Archives/edgar/data/1875558/000155837023003181/tmb-20221231x10k.htm)
- [FY 2021 MD&A](/company/NVCT/mda/fy2021/): filed 2022-03-23; accession 0001104659-22-037110 (https://www.sec.gov/Archives/edgar/data/1875558/000110465922037110/tm2210237d1_10k.htm)

Back to /company/NVCT/